Abnormal phosphorylation of human LRH1 at Ser510 predicts poor prognosis and promotes cell viability in lung squamous cell carcinoma

Abstract The nuclear receptor liver receptor homolog 1 (LRH1)/NR5A2 is aberrantly expressed in diverse cancer types, including liver and lung cancers. Since we previously showed that excessive phosphorylation of human LRH1 at S510 (hLRH1pS510-high) is predictable of hepatocellular carcinoma recurren...

Full description

Saved in:
Bibliographic Details
Main Authors: Hayato Mine, Kotaro Sugimoto, Makoto Kobayashi, Hironori Takagi, Naoyuki Okabe, Satoshi Muto, Yasuyuki Kobayashi, Yuko Hashimoto, Hiroyuki Suzuki, Hideki Chiba
Format: Article
Language:English
Published: BMC 2025-04-01
Series:BMC Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12885-025-14160-6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849311110343163904
author Hayato Mine
Kotaro Sugimoto
Makoto Kobayashi
Hironori Takagi
Naoyuki Okabe
Satoshi Muto
Yasuyuki Kobayashi
Yuko Hashimoto
Hiroyuki Suzuki
Hideki Chiba
author_facet Hayato Mine
Kotaro Sugimoto
Makoto Kobayashi
Hironori Takagi
Naoyuki Okabe
Satoshi Muto
Yasuyuki Kobayashi
Yuko Hashimoto
Hiroyuki Suzuki
Hideki Chiba
author_sort Hayato Mine
collection DOAJ
description Abstract The nuclear receptor liver receptor homolog 1 (LRH1)/NR5A2 is aberrantly expressed in diverse cancer types, including liver and lung cancers. Since we previously showed that excessive phosphorylation of human LRH1 at S510 (hLRH1pS510-high) is predictable of hepatocellular carcinoma recurrence, we here clarified the clinicopathological and biological significance of hLRH1pS510-high in lung cancer. By immunohistochemistry using an anti-hLRH1pS510 monoclonal antibody, we evaluated the hLRH1pS510 signals in 151 and 150 cases of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) tissues, respectively, and performed clinicopathological analysis. hLRH1pS510 was localized in the nucleus of tumor cells in LUAD and LUSC tissues with different intensity and proportions among the patients. Of note, the strong hLRH1pS510 signal was occasionally detectable in LUAD and LUSC cells at the expanding tumor edges. A semi-quantitative analysis revealed that 28 (18.4%) and 36 (24.0%) of LUAD and LUSC cases, respectively, exhibited hLRH1pS510-high. Kaplan-Meier plots showed significant differences in the disease-free survival (DFS) between the hLRH1pS510-high and hLRH1pS510-low groups in LUSC, but not in LUAD patients. hLRH1pS510-high was also significantly correlated with recurrence in LUSC patients. Additionally, by multivariate analysis, hLRH1pS510-high represented an independent biomarker for the DFS of LUSC patients. Furthermore, the impact of hLRH1pS510 on the viability of LUSC cells was evaluated by comparing phenotypes among two distinct LUSC cell lines expressing wild-type LRH1, LRH1S510A, and LRH1S510E. Consequently, we demonstrated that phosphorylation of hLRH1S510 accelerates the viability of LUSC cells. Thus, hLRH1pS510 is attractive not only as the predictive biomarker for LUSC but also as the potential therapeutic target.
format Article
id doaj-art-77f987f3e71a4a3dac58dda2072faefb
institution Kabale University
issn 1471-2407
language English
publishDate 2025-04-01
publisher BMC
record_format Article
series BMC Cancer
spelling doaj-art-77f987f3e71a4a3dac58dda2072faefb2025-08-20T03:53:32ZengBMCBMC Cancer1471-24072025-04-0125111210.1186/s12885-025-14160-6Abnormal phosphorylation of human LRH1 at Ser510 predicts poor prognosis and promotes cell viability in lung squamous cell carcinomaHayato Mine0Kotaro Sugimoto1Makoto Kobayashi2Hironori Takagi3Naoyuki Okabe4Satoshi Muto5Yasuyuki Kobayashi6Yuko Hashimoto7Hiroyuki Suzuki8Hideki Chiba9Department of Basic Pathology, Fukushima Medical University School of MedicineDepartment of Basic Pathology, Fukushima Medical University School of MedicineDepartment of Basic Pathology, Fukushima Medical University School of MedicineDepartment of Chest Surgery, Fukushima Medical University School of MedicineDepartment of Chest Surgery, Fukushima Medical University School of MedicineDepartment of Chest Surgery, Fukushima Medical University School of MedicineDepartment of Diagnostic Pathology, Fukushima Medical University School of MedicineDepartment of Diagnostic Pathology, Fukushima Medical University School of MedicineDepartment of Chest Surgery, Fukushima Medical University School of MedicineDepartment of Basic Pathology, Fukushima Medical University School of MedicineAbstract The nuclear receptor liver receptor homolog 1 (LRH1)/NR5A2 is aberrantly expressed in diverse cancer types, including liver and lung cancers. Since we previously showed that excessive phosphorylation of human LRH1 at S510 (hLRH1pS510-high) is predictable of hepatocellular carcinoma recurrence, we here clarified the clinicopathological and biological significance of hLRH1pS510-high in lung cancer. By immunohistochemistry using an anti-hLRH1pS510 monoclonal antibody, we evaluated the hLRH1pS510 signals in 151 and 150 cases of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) tissues, respectively, and performed clinicopathological analysis. hLRH1pS510 was localized in the nucleus of tumor cells in LUAD and LUSC tissues with different intensity and proportions among the patients. Of note, the strong hLRH1pS510 signal was occasionally detectable in LUAD and LUSC cells at the expanding tumor edges. A semi-quantitative analysis revealed that 28 (18.4%) and 36 (24.0%) of LUAD and LUSC cases, respectively, exhibited hLRH1pS510-high. Kaplan-Meier plots showed significant differences in the disease-free survival (DFS) between the hLRH1pS510-high and hLRH1pS510-low groups in LUSC, but not in LUAD patients. hLRH1pS510-high was also significantly correlated with recurrence in LUSC patients. Additionally, by multivariate analysis, hLRH1pS510-high represented an independent biomarker for the DFS of LUSC patients. Furthermore, the impact of hLRH1pS510 on the viability of LUSC cells was evaluated by comparing phenotypes among two distinct LUSC cell lines expressing wild-type LRH1, LRH1S510A, and LRH1S510E. Consequently, we demonstrated that phosphorylation of hLRH1S510 accelerates the viability of LUSC cells. Thus, hLRH1pS510 is attractive not only as the predictive biomarker for LUSC but also as the potential therapeutic target.https://doi.org/10.1186/s12885-025-14160-6Nuclear receptorNR5A2Liver receptor homolog 1Lung cancerLung adenocarcinomaBiomarker
spellingShingle Hayato Mine
Kotaro Sugimoto
Makoto Kobayashi
Hironori Takagi
Naoyuki Okabe
Satoshi Muto
Yasuyuki Kobayashi
Yuko Hashimoto
Hiroyuki Suzuki
Hideki Chiba
Abnormal phosphorylation of human LRH1 at Ser510 predicts poor prognosis and promotes cell viability in lung squamous cell carcinoma
BMC Cancer
Nuclear receptor
NR5A2
Liver receptor homolog 1
Lung cancer
Lung adenocarcinoma
Biomarker
title Abnormal phosphorylation of human LRH1 at Ser510 predicts poor prognosis and promotes cell viability in lung squamous cell carcinoma
title_full Abnormal phosphorylation of human LRH1 at Ser510 predicts poor prognosis and promotes cell viability in lung squamous cell carcinoma
title_fullStr Abnormal phosphorylation of human LRH1 at Ser510 predicts poor prognosis and promotes cell viability in lung squamous cell carcinoma
title_full_unstemmed Abnormal phosphorylation of human LRH1 at Ser510 predicts poor prognosis and promotes cell viability in lung squamous cell carcinoma
title_short Abnormal phosphorylation of human LRH1 at Ser510 predicts poor prognosis and promotes cell viability in lung squamous cell carcinoma
title_sort abnormal phosphorylation of human lrh1 at ser510 predicts poor prognosis and promotes cell viability in lung squamous cell carcinoma
topic Nuclear receptor
NR5A2
Liver receptor homolog 1
Lung cancer
Lung adenocarcinoma
Biomarker
url https://doi.org/10.1186/s12885-025-14160-6
work_keys_str_mv AT hayatomine abnormalphosphorylationofhumanlrh1atser510predictspoorprognosisandpromotescellviabilityinlungsquamouscellcarcinoma
AT kotarosugimoto abnormalphosphorylationofhumanlrh1atser510predictspoorprognosisandpromotescellviabilityinlungsquamouscellcarcinoma
AT makotokobayashi abnormalphosphorylationofhumanlrh1atser510predictspoorprognosisandpromotescellviabilityinlungsquamouscellcarcinoma
AT hironoritakagi abnormalphosphorylationofhumanlrh1atser510predictspoorprognosisandpromotescellviabilityinlungsquamouscellcarcinoma
AT naoyukiokabe abnormalphosphorylationofhumanlrh1atser510predictspoorprognosisandpromotescellviabilityinlungsquamouscellcarcinoma
AT satoshimuto abnormalphosphorylationofhumanlrh1atser510predictspoorprognosisandpromotescellviabilityinlungsquamouscellcarcinoma
AT yasuyukikobayashi abnormalphosphorylationofhumanlrh1atser510predictspoorprognosisandpromotescellviabilityinlungsquamouscellcarcinoma
AT yukohashimoto abnormalphosphorylationofhumanlrh1atser510predictspoorprognosisandpromotescellviabilityinlungsquamouscellcarcinoma
AT hiroyukisuzuki abnormalphosphorylationofhumanlrh1atser510predictspoorprognosisandpromotescellviabilityinlungsquamouscellcarcinoma
AT hidekichiba abnormalphosphorylationofhumanlrh1atser510predictspoorprognosisandpromotescellviabilityinlungsquamouscellcarcinoma